Clarification18 Sept 2026, 08:42 am
Dr Reddy's Confirms HIV Prevention Drug Licensing Deal
AI Summary
Dr. Reddy's Laboratories has confirmed a voluntary licensing agreement with Gilead Sciences for an investigational once-yearly HIV prevention drug, lenacapavir. This clarification follows a news report and confirms the company's press release from September 17, 2026. The company stated that no negotiations were ongoing and there is no material information requiring disclosure beyond the press release. This move is part of Dr. Reddy's ongoing collaboration with Gilead Sciences.
Key Highlights
- Dr. Reddy's confirms voluntary license for Gilead's HIV prevention drug.
- Agreement pertains to investigational once-yearly lenacapavir.
- Confirms prior press release; no new material information disclosed.
- No ongoing negotiations or trading-related information to report.
Price Impact
More from DRREDDY